Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Impact of Fibroblast Growth Factor 23 (FGF-23) and Serum Phosphate on Allograft Function and Mortality in Kidney Allograft Recipients

This study is ongoing, but not recruiting participants.
Information provided by:
Ramathibodi Hospital Identifier:
First received: May 1, 2009
Last updated: December 16, 2009
Last verified: December 2009
The present study will examine whether serum FGF-23 and serum phosphate at baseline of kidney transplant recipients can predict progression of allograft dysfunction at 3 years and all-cause mortality at 5 years.

Kidney Transplantation

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Impact of FGF-23 and Serum Phosphate on Allograft Function and Mortality in Kidney Allograft Recipients

Resource links provided by NLM:

Further study details as provided by Ramathibodi Hospital:

Primary Outcome Measures:
  • Progression of allograft dysfunction and all-cause Mortality [ Time Frame: 3 and 5 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Relationship of FGF-23 and 25-OH-D, 1-25-OH-D, PTH, calcium, phosphate, urine phosphate and eGFR [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

Estimated Enrollment: 200
Study Start Date: May 2009
Estimated Study Completion Date: January 2015
Estimated Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)
Kidney transplant recipients


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Kidney transplant recipients

Inclusion Criteria:

  • at least one year post-transplantation
  • no more than 10% increase in serum creatinine for the past 3 months

Exclusion Criteria:

  • refuse to participate in the study
  • any acute illnesses
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00903578

Ramathibodi Hospital, Mahidol University
Phayathai, Bangkok, Thailand, 10400
Sponsors and Collaborators
Ramathibodi Hospital
Principal Investigator: Sinee Disthabanchong, M.D. Ramathibodi Hospital, Mahidol University
  More Information

Responsible Party: Sinee Disthabanchong, M.D, Ramathibodi Hospital, Mahidol University Identifier: NCT00903578     History of Changes
Other Study ID Numbers: KT-1 
Study First Received: May 1, 2009
Last Updated: December 16, 2009
Health Authority: Thailand: Ethical Committee

Keywords provided by Ramathibodi Hospital:
vitamin D
allograft dysfunction
mortality processed this record on January 14, 2017